07:00 , Sep 22, 2014 |  BC Week In Review  |  Clinical News

Debio 1450 regulatory update

Debiopharm said FDA granted Qualified Infectious Disease Product (QIDP) designation to Debio 1450 to treat acute bacterial skin and skin structure infections (ABSSSI). The small molecule prodrug inhibitor of the bacterial fabI enoyl-(acyl carrier...
07:00 , Jul 14, 2014 |  BC Week In Review  |  Company News

Debiopharm Grou, Nobelex deal

Debiopharm partnered with Nobelex to develop two antibiotic programs targeting Neisseria gonorrhea and enteric species utilizing a novel mechanism of action. Debiopharm will retain rights to all IP developed under the deal. Debiopharm acquired the...
07:00 , Jun 23, 2014 |  BC Week In Review  |  Clinical News

oral Debio 1450: Phase I started

Debiopharm began a double-blind, placebo-controlled, U.S. Phase I trial to evaluate single ascending-doses of oral Debio 1450 in up to 48 healthy subjects. An IV formulation of the product is in Phase I testing. Debiopharm...
07:00 , Jun 9, 2014 |  BioCentury  |  Finance

Banker tracks

Banker tracks Maarten de Jong will join Moelis & Co.(NYSE:MC) in August as a managing director focused on healthcare. de Jong was a managing director at Barclays plc (NYSE:BCS). Private equity tracks Sudhir Bahl joined TVM Capital Healthcare...
08:00 , Feb 17, 2014 |  BC Week In Review  |  Company News

Affinium, Debiopharm deal

Debiopharm acquired all of the drug development assets of antibiotics company Affinium, which will now wind down operations. Debiopharm declined to disclose financial details. Affinium's technology is used for structure-guided discovery of fatty acid...
01:58 , Feb 12, 2014 |  BC Extra  |  Company News

Debiopharm acquires Affinium's antibiotic assets

Debiopharm Group (Lausanne, Switzerland) acquired all of the assets of antibiotics company Affinium Pharmaceuticals Ltd. (Austin, Texas), which will now wind down operations. Financial terms of the deal were not disclosed. The assets include Affinium's...
08:00 , Nov 18, 2013 |  BC Week In Review  |  Clinical News

AFN-1252 regulatory update

Affinium said FDA granted Qualified Infectious Disease Product (QIDP) designation for AFN-1252 to treat acute bacterial skin and skin structure infections (ABSSSI). The small molecule inhibitor of the bacterial fabI enoyl-(acyl carrier protein) reductase...
07:00 , Sep 16, 2013 |  BC Week In Review  |  Clinical News

AFN-1720: Phase I started

Affinium began a placebo-controlled Phase I trial to evaluate single ascending-doses of IV AFN-1720 in healthy volunteers. The compound is a prodrug of Affinium's AFN-1252, which is in Phase II testing to treat acute...
07:00 , Sep 9, 2013 |  BC Week In Review  |  Financial News

Affinium completes venture financing

Affinium Pharmaceuticals Ltd., Austin, Texas   Business: Infectious, Computational chemistry/biology   Date completed: 9/4/13   Type: Venture financing   Raised: Not disclosed   Investors: Existing investors   Note: Affinium raised an undisclosed amount in an extension of an undisclosed venture round....
07:00 , Apr 1, 2013 |  BC Week In Review  |  Clinical News

AFN-1252: Phase IIa data

An open-label, U.S. and Canadian Phase IIa trial in 103 patients with ABSSSI due to Staphylococcus showed that twice-daily 200 mg oral AFN-1252 for 5-14 days led to an overall cure rate, defined as resolution...